These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 17826491

  • 1. Effect of definition of preradiotherapy prostate-specific antigen velocity on its association with prostate cancer-specific mortality and all-cause mortality.
    Nguyen PL, Chen MH, Renshaw AA, Sussman B, D'Amico AV.
    Urology; 2007 Aug; 70(2):288-93. PubMed ID: 17826491
    [Abstract] [Full Text] [Related]

  • 2. Six-month androgen suppression plus radiation therapy compared with radiation therapy alone for men with prostate cancer and a rapidly increasing pretreatment prostate-specific antigen level.
    D'Amico AV, Loffredo M, Renshaw AA, Loffredo B, Chen MH.
    J Clin Oncol; 2006 Sep 01; 24(25):4190-5. PubMed ID: 16943536
    [Abstract] [Full Text] [Related]

  • 3. Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality.
    Chung CS, Chen MH, Cullen J, McLeod D, Carroll P, D'Amico AV.
    Urology; 2008 Jan 01; 71(1):136-40. PubMed ID: 18242382
    [Abstract] [Full Text] [Related]

  • 4. Pretreatment prostate-specific antigen velocity is associated with development of distant metastases and prostate cancer mortality in men treated with radiotherapy and androgen-deprivation therapy.
    Palma D, Tyldesley S, Pickles T, Prostate Cohort Outcomes Initiative.
    Cancer; 2008 May 01; 112(9):1941-8. PubMed ID: 18338814
    [Abstract] [Full Text] [Related]

  • 5. Prostate-specific antigen recurrence and mortality after conventional dose radiation therapy in select men with low-risk prostate cancer.
    Petit JH, Chen MH, Loffredo M, Sussman B, Renshaw AA, D'Amico AV.
    Cancer; 2006 Nov 01; 107(9):2180-5. PubMed ID: 17009323
    [Abstract] [Full Text] [Related]

  • 6. Predictors of prostate cancer-specific mortality in elderly men with intermediate-risk prostate cancer treated with brachytherapy with or without external beam radiation therapy.
    Nanda A, Chen MH, Moran BJ, Braccioforte MH, Dosoretz D, Salenius S, Katin M, Ross R, D'Amico AV.
    Int J Radiat Oncol Biol Phys; 2010 May 01; 77(1):147-52. PubMed ID: 19744800
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Time to an undetectable prostate-specific antigen (PSA) after androgen suppression therapy for postoperative or postradiation PSA recurrence and prostate cancer-specific mortality.
    D'Amico AV, McLeod DG, Carroll PR, Cullen J, Chen MH.
    Cancer; 2007 Apr 01; 109(7):1290-5. PubMed ID: 17315162
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Prostate-specific antigen velocity and prostate cancer gleason grade and stage.
    Pinsky PF, Andriole G, Crawford ED, Chia D, Kramer BS, Grubb R, Greenlee R, Gohagan JK.
    Cancer; 2007 Apr 15; 109(8):1689-95. PubMed ID: 17330856
    [Abstract] [Full Text] [Related]

  • 11. Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality.
    Efstathiou JA, Chen MH, Catalona WJ, McLeod DG, Carroll PR, Moul JW, Roehl KA, D'Amico AV.
    Urology; 2006 Aug 15; 68(2):342-7. PubMed ID: 16904449
    [Abstract] [Full Text] [Related]

  • 12. Relapse after radical prostatectomy correlates with preoperative PSA velocity and tumor volume: results from a screening population.
    Berger AP, Deibl M, Strasak A, Bektic J, Pelzer A, Steiner H, Spranger R, Fritsche G, Bartsch G, Horninger W.
    Urology; 2006 Nov 15; 68(5):1067-71. PubMed ID: 17095070
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Surrogate end point for prostate cancer specific mortality in patients with nonmetastatic hormone refractory prostate cancer.
    D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH.
    J Urol; 2005 May 15; 173(5):1572-6. PubMed ID: 15821488
    [Abstract] [Full Text] [Related]

  • 15. Influence of body mass index on prostate-specific antigen failure after androgen suppression and radiation therapy for localized prostate cancer.
    Efstathiou JA, Chen MH, Renshaw AA, Loffredo MJ, D'Amico AV.
    Cancer; 2007 Apr 15; 109(8):1493-8. PubMed ID: 17340594
    [Abstract] [Full Text] [Related]

  • 16. Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factors.
    D'Amico AV, Chen MH, Catalona WJ, Sun L, Roehl KA, Moul JW.
    Cancer; 2007 Jul 01; 110(1):56-61. PubMed ID: 17530618
    [Abstract] [Full Text] [Related]

  • 17. Postradiotherapy 2-year prostate-specific antigen nadir as a predictor of long-term prostate cancer mortality.
    Zelefsky MJ, Shi W, Yamada Y, Kollmeier MA, Cox B, Park J, Seshan VE.
    Int J Radiat Oncol Biol Phys; 2009 Dec 01; 75(5):1350-6. PubMed ID: 19515504
    [Abstract] [Full Text] [Related]

  • 18. Pretreatment PSA velocity as a predictor of disease outcome following radical radiation therapy.
    Palma D, Tyldesley S, Blood P, Liu M, Morris J, Pickles T, Prostate Cohort Outcomes Initiative.
    Int J Radiat Oncol Biol Phys; 2007 Apr 01; 67(5):1425-9. PubMed ID: 17394943
    [Abstract] [Full Text] [Related]

  • 19. Effect of obesity on prostate-specific antigen recurrence after radiation therapy for localized prostate cancer as measured by the 2006 Radiation Therapy Oncology Group-American Society for Therapeutic Radiation and Oncology (RTOG-ASTRO) Phoenix consensus definition.
    Stroup SP, Cullen J, Auge BK, L'Esperance JO, Kang SK.
    Cancer; 2007 Sep 01; 110(5):1003-9. PubMed ID: 17614338
    [Abstract] [Full Text] [Related]

  • 20. Impact of obesity on the utility of preoperative prostate-specific antigen velocity to predict for relapse after prostatectomy: a report from the SEARCH database.
    King CR, Freedland SJ, Terris MK, Kane CJ, Amling CL, Aronson WJ, Presti JC.
    Urology; 2007 May 01; 69(5):921-6. PubMed ID: 17482935
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.